CTOs on the Move

Moderna Therapeutics

www.modernatx.com

 
Moderna is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.modernatx.com
  • 200 Technology Square
    Cambridge, MA USA 02139
  • Phone: 617.714.6500

Executives

Name Title Contact Details
Brad Miller
Chief Information Officer Profile
Marcello Damiani
Chief Digital Officer Profile
Jerh Collins
Chief Technical Operations and Quality Officer Profile
Adrian Stone
Senior Vice President and Chief Information Security Officer Profile

Funding

Moderna Therapeutics raised $650M on 01/12/2016
Moderna Therapeutics raised $483M on 04/17/2020
Moderna Therapeutics raised $472M on 07/24/2020

Similar Companies

EUSA Pharma Corporation

EUSA Pharma Corporation is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celladon

Celladon is a privately held biotechnology company founded with the goal of developing molecular therapies for cardiovascular diseases. Breakthroughs in the basic understanding of the cardiovascular networks combined with powerful new technologies have provided the foundation for new, rational, and technologically sophisticated approaches to cardiovascular treatments. Our first product candidate is designed to target the key enzyme deficiency in advanced heart failure which regulates calcium cycling and contractility in heart muscle cells.

Elixirgen Therapeutics

A clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines

Curve Biosciences

Curve Biosciences (“Curve”), a company bringing precision to chronic disease care, creates products targeting biological changes in tissues that result in the development and progression of chronic diseases. Curve`s Chronic Disease Tissue Atlas (CDTA) uniquely allows the company to discover these precise changes with data from over 250,000 tissues across more than 1,000 clinical studies. Curve is focused on first commercializing its best-in-class blood tests for the $30 billion market of chronic liver diseases while using CDTA to find biomarkers and targets for other conditions.

Avrobio

AVROBIO`s vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by our industry leading plato® gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario.